Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

•Cediranib is an oral VEGF receptor kinase inhibitor and ICON6 explored its activity in recurrent ovarian cancer.•In a randomised trial cediranib with chemotherapy and as maintenance significantly prolonged PFS.•Cessation of cediranib supply led to a reduction in sample size and OS was underpowered.•A mature survival analysis showed a non-significant increase in the median and Restricted Mean Survival Time (RMST) with cediranib.•There was a clinical benefit of cediranib but further research is needed to determine its role in recurrent ovarian cancer.